Furthermore, combining IL-4 blockade strategies with existing immunotherapeutic approaches [e.g. immune checkpoint inhibitors (221) or CAR-T therapy (222)] may improve therapeutic efficacy and advance clinical intervention for gastritis, GC and other related diseases. Here, IL4 is linked to gastritis.